Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Reports Preliminary Q4 Revenues of $355M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bruker said Thursday after the close of the market that it expects to report total revenue for the fourth quarter of more than $355 million.

The updated preliminary results follow its Jan. 13 announcement, when the company had said that revenues for the quarter would be greater than $340 million. GAAP operating margin for Bruker Scientfic Instruments is now projected to exceed 18 percent, the company added. However, it did not provide a revenue figure.

Revenue for Bruker Energy & Supercon Technologies is anticipated to exceed $20 million, a 75 percent improvement over Q4 2008 results. Operating loss for the division is expected to shrink, the company said without elaborating.

Bruker is scheduled to release its fourth-quarter and full-year 2009 results on Feb. 25.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.